Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | ACP1 | P24666 | 2/20 | 0.32 |
| ▸ | CDC25B | P30305 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133975 | 1.00 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBCYP1A2 | |
| SCHEMBL6907971 | 1.00 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBCYP1A2 | |
| SCHEMBL9618602 | 1.00 | ALDH1A1 (0.44) | ALDH1A1EPHX1TSHRTHRBCYP1A2 | |
| SCHEMBL9133960 | 0.97 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBCYP1A2 | |
| SCHEMBL1261859 | 0.90 | — | — | |
| SCHEMBL15719397 | 0.81 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL17679182 | 0.81 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL13441848 | 0.78 | ALDH1A1 (0.48) | ALDH1A1EPHX1TSHRTHRBCYP1A2 | |
| SCHEMBL8968579 | 0.78 | ALDH1A1 (0.43) | ALDH1A1EPHX1TSHRTHRBSPHK1 | |
| SCHEMBL6907848 | 0.76 | ALDH1A1 (0.41) | ALDH1A1EPHX1TSHRTHRBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686483-B2 | REACTING AN OXIDIZER WITH AN OLEFIN IN PRESENCE OF KETONE | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| EP-1021426-B1 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020133031-A1 | Catalytic asymmetric epoxidation | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-09-19 | — | — | US | disclosed |
| US-6348608-B1 | ADDING OXIDIZING AGENT TO REACTION SOLUTION COMPRISING CHIRAL CYCLIC ENANTIOMERICALLY ENRICHED KETONE AND OLEFIN UNDER CONDITIONS EFFECTIVE TO GENERATE ENANTIOMERICALLY ENRICHED EPOXIDE, SEPARATING EPOXIDE FROM REACTION SOLUTION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-02-19 | — | — | US | disclosed |
| EP-1021426-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021426-A4 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998015544-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133031-A1 | Catalytic asymmetric epoxidation | CBR1, AOX1, CBR3 | ALDH1A1 133/4885EPHX1 29/4885TSHR 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.